| Q60912555 | A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis |
| Q34412381 | Advances in understanding of bile acid diarrhea |
| Q57118481 | Alterations in gut microbial function following liver transplant |
| Q38623328 | Antibiotic prophylaxis in cirrhosis: Good and bad. |
| Q53686005 | BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection. |
| Q35645328 | Baicalein reduces the occurrence of cirrhotic endotoxemia by reducing intestinal mucosal apoptosis |
| Q93349075 | Bile Acid 7α-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of Secondary Bile Acids |
| Q28086845 | Bile Acid diarrhea: prevalence, pathogenesis, and therapy |
| Q34425909 | Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer |
| Q28244875 | Bile acid signaling in metabolic disease and drug therapy |
| Q34432618 | Bile acids and the gut microbiome |
| Q36191276 | Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242. |
| Q55322856 | Changes of Intestinal Functions in Liver Cirrhosis. |
| Q37323321 | Characterization of AQPs in Mouse, Rat, and Human Colon and Their Selective Regulation by Bile Acids. |
| Q33627590 | Circulating bile acids predict outcome in critically ill patients |
| Q35790974 | Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis |
| Q58740370 | Clinical impact of microbiome in patients with decompensated cirrhosis |
| Q52720224 | Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids. |
| Q34121950 | Colonic inflammation and secondary bile acids in alcoholic cirrhosis |
| Q54967548 | Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. |
| Q38914938 | Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota. |
| Q57108614 | Comprehensive Functional Analysis of the Enterococcus faecalis Core Genome Using an Ordered, Sequence-Defined Collection of Insertional Mutations in Strain OG1RF |
| Q57112038 | Dietary soybean protein ameliorates high-fat diet-induced obesity by modifying the gut microbiota-dependent biotransformation of bile acids |
| Q90603645 | Diversification of host bile acids by members of the gut microbiota |
| Q26775927 | Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications |
| Q33851866 | Effects of Low-Dose Non-Caloric Sweetener Consumption on Gut Microbiota in Mice. |
| Q36970524 | Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome |
| Q46376865 | Evidence of distinct pathways for bacterial degradation of the steroid compound cholate suggests the potential for metabolic interactions by interspecies cross-feeding. |
| Q91639788 | Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial |
| Q91663832 | Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor |
| Q41706834 | Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step |
| Q28083295 | Gut Microbiota and Host Reaction in Liver Diseases |
| Q36100831 | Gut Microbiota: Modulation of Host Physiology in Obesity |
| Q54948497 | Gut microbial composition can differentially regulate bile acid synthesis in humanized mice. |
| Q37251311 | Gut microbiome alterations in patients with stage 4 hepatitis C. |
| Q33779218 | Gut microbiota influences low fermentable substrate diet efficacy in children with irritable bowel syndrome |
| Q35653362 | Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut |
| Q28084576 | Gut microbiota: its role in hepatic encephalopathy |
| Q26826919 | Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia |
| Q30234574 | Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management |
| Q46246381 | High-resolution profiling of the gut microbiome reveals the extent of Clostridium difficile burden |
| Q39111416 | Impact of Dietary Fibers on Nutrient Management and Detoxification Organs: Gut, Liver, and Kidneys |
| Q90060560 | Impact of Rifaximin Therapy on Ischemia/Reperfusion Injury in Liver Transplantation: A Propensity Score-Matched Analysis |
| Q36013358 | Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract |
| Q41634474 | In vivo therapeutic effect of combination treatment with metformin and Scutellaria baicalensis on maintaining bile acid homeostasis |
| Q50073183 | Influence of Bile Acids on Colorectal Cancer Risk: Potential Mechanisms Mediated by Diet - Gut Microbiota Interactions |
| Q36204422 | Interaction of gut microbiota with bile acid metabolism and its influence on disease states |
| Q42372550 | Interactions between Bacteria and Bile Salts in the Gastrointestinal and Hepatobiliary Tracts |
| Q35684716 | Interactions between the intestinal microbiota and bile acids in gallstones patients |
| Q64891371 | Intervening Effects of Total Alkaloids of Corydalis saxicola Bunting on Rats With Antibiotic-Induced Gut Microbiota Dysbiosis Based on 16S rRNA Gene Sequencing and Untargeted Metabolomics Analyses. |
| Q35247159 | Intestinal transport and metabolism of bile acids |
| Q55311464 | Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections. |
| Q92992822 | Metagenomic analysis of bile salt biotransformation in the human gut microbiome |
| Q39363389 | Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification |
| Q34647371 | Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis |
| Q42651339 | Microbiota-related Changes in Bile Acid & Tryptophan Metabolism are Associated with Gastrointestinal Dysfunction in a Mouse Model of Autism |
| Q26741117 | Mucosal Interactions between Genetics, Diet, and Microbiome in Inflammatory Bowel Disease |
| Q34589677 | Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development |
| Q57147768 | Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation |
| Q47389652 | Reciprocal interactions between bile acids and gut microbiota in human liver diseases. |
| Q48462438 | Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. |
| Q27693345 | Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective. |
| Q64077761 | Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship |
| Q90163452 | Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD |
| Q39602278 | Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis |
| Q50948793 | Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats. |
| Q64283346 | Synbiotic-driven improvement of metabolic disturbances is associated with changes in the gut microbiome in diet-induced obese mice |
| Q47283908 | Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications |
| Q91551891 | Targeted bile acids and gut microbiome profiles reveal the hepato-protective effect of WZ tablet (Schisandra sphenanthera extract) against LCA-induced cholestasis |
| Q37082666 | Taurocholic acid metabolism by gut microbes and colon cancer |
| Q58795034 | The Misunderstood Coagulopathy of Liver Disease: A Review for the Acute Setting |
| Q35019661 | The gut microbiota and the liver: implications for clinical practice |
| Q57112600 | The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism |
| Q39262148 | The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis |
| Q34129402 | The role of microbiota in hepatic encephalopathy |
| Q61812480 | The role of the microbiome in NAFLD and NASH |
| Q33648565 | Three measurable and modifiable enteric microbial biotransformations relevant to cancer prevention and treatment |
| Q64899414 | Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats. |
| Q40361105 | Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice. |
| Q103805824 | Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure |